Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Yonsei University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07237308CT.gov BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis | — | Not Yet Recruiting | — | — | — |
NCT06486792CT.gov Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation | — | Recruiting | — | — | — |
NCT04809818CT.gov A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects | — | Completed | — | — | — |
NCT06144866CT.gov Evaluataion of NOAC Levels in Acute Stroke | — | Unknown | — | — | — |
NCT03961334CT.gov MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention | — | Unknown | — | — | — |
NCT04435418CT.gov Eliquis Acute Stroke Safety Evaluation | — | Completed | — | — | — |
NCT03568916CT.gov Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs) | — | Completed | — | — | — |
NCT02818868CT.gov Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial | — | Completed | — | — | — |
NCT01924325CT.gov Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apixaban (this asset) | Yonsei University | Approved | BB · 66 |
| Ticagrelor | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Compound Edaravone | Nanfang Hospital, Southern Medical University | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Nanfang Hospital, Southern Medical University | P4 | BBB |
| Argatroban | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Tenecteplase | Hackensack Meridian Health | P4 | BBB |
| Prednisolone | University of California, San Francisco | P4 | BB |
| Clopidogrel | Nanfang Hospital, Southern Medical University | P4 | BB |
+42 more in the Ischemic Stroke cohort
Other indications for Apixaban
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | BBB · 79 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Transient Ischemic Attack | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apixaban in Ischemic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apixaban-ischemic-stroke
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →